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The enterochromaffin-like (ECL) cells, the most frequent endocrine cells ofthe
oxyntic mucosa ofthe stomach, are under the trophic stimulus ofgastrin. These
cells undergo a hyperplastic increase in variety of hypergastrinemic diseases.
The most widely accepted nomenclature for the description ofhyperplastic pro-
liferation has been retrospectively arranged in a sequence presumed to reflect a
temporal evolution of the proliferative process. A comparative, prospective
study aimed to verify, in human hypergastrinemic diseases such as atrophic
body gastritis (ABG), Zollinger-Ellison syndrome (ZES) and antral gastrin cell
hyperfunction (AGCH), the effect ofexposure ofECL cells to different pattern
ofgastrin hypersecretion, is lacking. To this purpose, we studied a series ofcon-
secutive patients with ABG, ZES and AGCH at the time of first diagnosis.
Material and Methods: The patients included in this study (124 ABG, 18 ZES
and 10AGCH) were selected on the basis oftwo previously performed screening
studies aimed to diagnose these diseases. All patients at the time of diagnosis
underwent gastroscopy, with multiple biopsies of the gastric body mucosa for
the evaluation ofqualitative pattern ofECL cells hyperplasia, and basal fasting
gastrin determination. A sample of hypergastrinemic patients from each group
was furtherinvestigated by meal-stimulation ofgastrin secretion andquantitative
morphometry for CgA positive gastric body endocrine cells. Results: AGCH
patients showed only the normal or simple hyperplasia pattern. In the ZES
group, simple and linear grades accounted for 38.4 percent and 46.1 percent,
respectively. MEN-I patients showed only these two patterns. The majority of
ABG patients showed the presence of micronodular pattern (59.7 percent). A
correlation analysis between fasting gastrin levels and grade of hyperplasia
(r = 0.5580, p <0.0001), indicates that the greater the gastrin levels, the higher is
the degree ofseverity ofECLhyperplasiapattern. In conclusion, ourdata support
the role of gastrin as the selective contributor to the progression of ECL cell
hyperplasia in humans.
INTRODUCTION
The enterochromaffm-like (ECL)b cells, the most frequent endocrine cells ofthe oxyntic
mucosa of the stomach, are under the trophic stimulus of gastrin. In fact, they have been
shown toproliferate in experimental [1] andpathologic [2-3] states associated with hyper-
gastrinemia. The hyperplastic response of the ECL cells to hypergastrinemia, either
endogenous or exogenous, has been observed in rodents in elegant studies performed by
Hakanson and co-workers [4]. Ifthegastrin stimulus was sustained fordays, the ECLcells
responded with hypertrophy [4]. If the stimulus was further sustained for weeks and
months, a five-fold increase in ECL cell number (hyperplasia) developed [1, 5-6].
aTo whom all correspondence should be addressed: Gianfranco Delle Fave, M.D., II Clinica
Medica, Policlinico Umberto I°, Viale del Poiliclinico, 00161 Rome, Italy. Tel.: 39-06-4455292;
Fax: 39-06-4463737.
bAbbreviations: ECL, enterochromaffin-like (cells); ABG, atrophic body gastritis; ZES, Zollinger-
Ellison syndrome; MEN I, multiple endocrine neoplasia type I; AGCH, antral gastrin cell hyper-
function; TVD, total volume density; CgA, chromogranin A; SH, simple (or diffuse) hyperplasia;
LH, Linear hyperplasia; MH, micronodular hyperplasia; AH, adenomatoid hyperplasia.
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Although many experimental studies have been done on ECL cells with different
models of induced hypergastrinemia, studies involving humans are usually restricted to
patients with rare hypergastrinemic conditions such as atrophic body gastritis (ABG),
Zollinger-Ellison syndrome (ZES) and antral gastrin cell hyperfunction (AGCH).
Various nomenclature have been used to describe the qualitative histological patterns
ofgastric body mucosa endocrine cell in humans. The most widely accepted, formulated
by a panel of pathologists with specific interest in gastrointestinal endocrine pathology,
has been retrospectively arranged in a sequence presumed to reflect a temporal evolution
of the proliferative process [7]. This supposed successive development of increasingly
more advanced grades of ECL cell growth has been indirectly verified in the aforemen-
tionedexperimental animalmodels, in whichthe successive steps ofthequalitativepatterns
of hyperplasia observed in humans have been produced by sustained levels ofhypergas-
trinemia [8]. In addition, in these experimental conditions, the ECL cells also evolved to
dysplastic lesions and carcinoid tumors [8]. Thus, the experimental observations and the
occurrenceofsuchqualitative morphologic changes may suggest, as alsoinhumans, gastrin
acts as a promoter ofECL cell growth. In a recent study in patients with carcinoid arising
on ABG and ZES, it has been demonstrated by ultrastructural morphometry as gastrin
exerts a selective role onECLcell component ofthe endocrine cell population ofthe gastric
body mucosa, thus strengtheningthe specifictrophic actionofgastrinonhumanECLcells [9].
Qualitatively recognizable ECL cell hyperplasia in the human gastric mucosa has
been mainly investigated in two pathological conditions: atrophic body gastritis [10] and
Zollinger-Ellison syndrome [11]. ABG is characterized by chronic inflammation ofoxyntic
mucosa resulting in a progressive atrophy of the oxyntic glands and, subsequently,
achlorhydria [12]. The unopposed feedback due to achlorhydria determines a sustained
hypersecretion ofgastrin by the G cells located in the antrum. ABG is a consistent finding
in pernicious anemia, but can be found independently from it [13]. In ZES the hypergas-
trinemia is determined by agastrin-secreting tumor, mostly ofpancreatic orduodenal origin
[14]. The hypergastrinemia induces a state ofunremitting gastric acid hypersecretion and
recurrent ulcer peptic disease. In 25 percent ofthe cases [14], ZES can also be a manifes-
tation of the multiple endocrine neoplasia type 1 (MEN I), a disease characterized by an
inherited predisposition to develop endocrine tumors.
Another human disease associated with increased gastrin levels is the antral gastrin
cell hyperfunction (AGCH) syndrome, also known as pseudo-ZES. This syndrome is a
debated clinical entity described to occur with or without antral gastrin cell hyperplasia in
adults and in infants [15-16], probably reflecting one side of the spectrum of H. pylori-
related duodenal ulcer disease [17]. Few data concerning the ECL cell hyperplasia in this
rare condition are available, but a qualitative description ofthe pattern ofECLproliferation
is lacking.
In these three diseases, a significant correlation has been demonstrated between cir-
culating gastrin concentrations and ECL cell number [10, 18-20]. In addition, the entire
spectrum of qualitative ECL cell proliferation, from hyperplasia to dysplasia and to neo-
plasia, has been observed in patients with ABG and ZES [11]. However, most ofthe studies
regarding the prevalence ofECLcell pattern ofgrowth in these hypergastrinemic conditions
are retrospective in nature and based on filed histological specimens for which complete
functional data do not exist [7, 21]. In addition, a prospective comparative analysis ofthe
ECL cell changes present in these three human diseases has never been presented.
Another item that deserves attention is the possible role of stimulated gastrin levels
in contributing to ECL cells proliferation. The main stimulus for gastrin secretion is
constituted by the daily meals, which induce different gastrin response in the human
hypergastrinemic conditions. In fact, even though in ZES patients tumoral hypergas-
trinemia is independent from anyphysiological stimuli, bothABG andAGCH, characterized
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by G cells hyperplasia/hyperfunction, are greatly affected by stimulants such as meals
[22]. Thus, the role of different pattern of gastrin response to the meals and the conse-
quent different time and levels of exposure of human ECL cell to the specific trophic
hormone should also be taken in account in evaluating the relationship between gastrin
and its cellular target.
Aimofthe present study was to verify, in human hypergastrinemic diseases, the effect of
exposure ofECLcells todifferentpattern ofgastrinhypersecretion. To thispurpose, we studied
a series of consecutive patients with ABG, ZES and AGCH at the time offirst diagnosis.
MATERIALAND METHODS
Patients
The patients included in this study were selected on the basis oftwo screening studies.
The first concerned a screening program forearly detection ofABG inpatients with unex-
plained anemia or long-standing history of dyspepsia, as described in detail elsewhere
[13]. In the second study, ZES and AGCH patients were identified among a group of
patients with resistant duodenal ulcer, which represents one of the main clinical charac-
teristic ofthese diseases, as previously published [23].
Atrophic body gastritis. One-hundred and twenty-four patients (35 males and 89
females; age range: 22-83 [median: 56.5]) in whomABG was newly diagnosed from June
1991 to December 1996. The patients who were found to have gastrin values exceeding the
normal range at our laboratory were further investigated with test for gastric acid secretion
(basal and pentagastrin-stimulated) and underwent gastroscopy with multiple biopsies of
thegastric body mucosaforconventional histopathological examination andfortheevaluation
endocrine cells. Only patients with histologically proven ABG, irrespective of the type
[24], were included. Pernicious anemia was present in 48 patients (38.7 percent) (Table 1).
Zollinger-Ellison syndrome. Eighteen patients (12 males and six females; age range:
11-67 [median: 53.5]) in whom the diagnosis ofZES was established by demonstration of
repeated basal plasma hypergastrinemia, basal acid hypersecretion and positive secretin
test (plasma gastrin increase more than 200 pg/ml over basal value after IV bolus of 2
U/kg secretin) [25]. MEN-I was present in five patients (four males and one female-; 27.7
percent) (Table 1).
Antral gastrin cell hyperfunction. Ten patients (eight males and two females; age
range: 19-54 [median: 35.5]) defined by co-existence ofbasal and meal-stimulated gastrin
levels exceeding the normal range, a negative secretin test, an increased basal and/orpeak
acid output (BAO and PAO, respectively), as previously described [15-16, 23] (Table 1).
Control group. Seventeen individuals (two males and 15 females; age range: 21-67
[mean: 44.2]) with dyspeptic complaints but no histological findings of body mucosal
atrophy and normal fasting and stimulated gastrin values.
Biopsies
All patients investigated underwent gastroscopy with multiple biopsies ofthe gastric
body mucosa for the same morphological investigations performed in ABG patients. In
each patients three to four biopsies were obtained from the mid-part of the gastric body
mucosa approximately 4 to 5 cm above the corpus/antrum border along the great curve
and from the antral mucosa with the use of a fiberoptic gastroscope. Immediately after
recovery, the biopsy specimens were fixed in Bouin's fluid for three to four hours at room
temperature. After rinsing in 70 percent ethanol, they were alcohol dehydrated and
embedded in paraffin.
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Table 1. Clinical and biochemical features ofZollinger-Ellison (ZES),Antral G cell hyperpla-
sia (AGCH) and atrophic body gastritis (ABG) patients. Results are expressed as median
(range).
ZES AGCH ABG
n= 18a n= 10 n= 124b
Age (yrs) 53.5 35.5 56.5
(11-67) (19-54) (22-83)
Sex (male/female) 12/6 8/2 35/89
Basal serum gastrin (pg/mlW) 950 56.1 375
(235-8000) (45-77) (49-2700)
Basal acid output (mnEq/h) 48.8 15 0
(12-96) (11-22.4) (0-1.3)
Pentagastrin acid output (mEq/h) 57 46.5 0
(24-105) (24.7-96.1) (0-10)
alncluding 5 with MEN-1 (four males, one female).
b48 patients hadpernicious anemia.
cNormal value = 10-40 pg/ml.
Morphological investigations ofgastric body mucosa
Histology and Immunocytochemistry. Serial 5 jm-thick sections of gastric body
mucosa perpendicular to the mucosal surface were stained with hematoxylin-eosin for
conventional histopathological examination and for immunostaining of endocrine cells
using monoclonal antibody against chromogranin A (CgA; clone LK2H10, Biogenex
Laboratory, San Ramon, CA) followed by avidin-biotine complex procedure (Dako,
LSAB2 kit, Dakopatts, Glostrup, Denmark). Biotinylated goat antirabbit Igs (code
BA1000, VectorLaboratories, Burlingame, CA; dilution, 1:200) were thenused as asecondary
antibody, followed by the avidin-biotin-complex peroxidase technique (Vectastain ABC
Kit, VectorLaboratories, Burlingame, CA). Forthe immunoreaction, diaminobenzidine tetra-
hydrochloride was used as a chromogen substrate and nuclear counterstaining with hema-
toxylin was performed. Glandular atrophy ofthe body mucosa was defined as replacement
of oxyntic glands by metaplastic pyloric and/or intestinal glands [19].
The endocrine cell changes were evaluated in non-intestinalized areas ofgastric body
mucosa. The following patterns ofendocrine cell growth were identified according to the
classification proposed by Solcia et al. [7] and independently evaluated by two examiners
who were unaware of the patient's clinical data: 1) normal pattern; 2) simple (or diffuse)
hyperplasia (SH); 3) linear hyperplasia (LH); 4) micronodular hyperplasia (MH); and 5)
adenomatoid hyperplasia (AH). The patients were subdivided into different groups
according to the highest grade of endocrine cell hyperplasia [23]. Consequently, patients
with Normal and SH were assigned to the group of SH, those with both SH and LH were
assigned to the subgroup ofLH, those with both LH and MH were assigned to the group
of MH and those with both MH and AH were assigned to the group ofAH.
Morphometry. The methodological procedure employed in the study of the volume
density of all endocrine cells (identified by CgA immunostaining) has been described in
detail elsewhere [26]. On the basis of the stereological principle dictating that the area
fraction of any tissue component is equal to its volume fraction [27], the volume density
of endocrine cells was calculated as the fraction of the area of the epithelial mucosal
component (glandular luminaexcluded) occupied by immunostained endocrine cellprofiles
and the results were expressed as a percentage of the endocrine cell mass over the total
volume of the mucosal epithelial structures.
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Gastrin Assay and test meal
Plasma gastrin levels were determined by radioimmunoassay using antiserum 4562,
kindly supplied by Prof. J.F. Rehfeld, Copenhagen, Denmark, as previously described
[28]. This antiserum measures gastrin components I, II and III with almost equimolar
potency [29]. Plasma values are expressed as pg/ml equivalent ofSHG 171. Plasma gastrin
was measured in all patients. Previous evaluation of normal subjects in our laboratory
using this antibody showed that the normal range for basal gastrin was 10-40 pg/ml [24].
Aprotein-rich meal stimulation was performed, as described [15], in arepresentative sample
ofpatients from each group.
Statistics
Data were expressed as median (range) or number/total (percentage, percent).
Analyses were performed using the Mann-Whitney test for unpaired non parametric data.
The Spearman rank test was applied for correlation analysis. To evaluate the relationship
between gastrin values and qualitative pattern ofECL cell growth, each pattern was graded
as follows: normal pattern = 1; simple = 2; linear = 3; micronodular =4; adenomatoid = 5.
Two-tailed P values less than 0.05 were considered statistically significant.
RESULTS
The respective percentage ofECLpattern hyperplasia in each group ofthe investigated
hypergastrinemic patients at the time ofdiagnosis is shown in Figure 1. Both controls and
the AGCH patients showed only the normal or SH pattern. However, in the controls, the
normal pattern predominated, whereas the AGCH group showed a predominance of the
SH pattern. In the ZES group Normal pattern ofECL cells was not observed, hyperplastic
changes were mainly composed by the Simple and Lineargrades accounting for 38.4 per-
cent and 46.1 percent respectively, and in the MEN-I group the same patterns were found.











Figure 1. Relative percentage of qualitative pattern of ECL cell in each group of hypergas-
trinemic patients and controls investigated. * = Normal pattern; 2 = Simple hyperplasia pattern;
] = Linear hyperplasia pattern; E = Micronodular hyperplasia pattern; L4] = Adenomatoid hyper-
plasia pattern.
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Table 2. Median (range) of fasting gastrin levels in hypergastrinemic patients at the time of
diagnosis subdivided according to the qualitative pattern ofendocrine (ECL) cellsa.
Normal SH LH MH AH
ZES 440 1050 350 8000
(235-2205) (315-2625)
n= 18 n=0 n=9 n=7 n= 1 n=1
AGCH 51.5 59 - - -
(45-58.6) (45-77.3)
n= 10 n=4 n=6 n=0 n=0 n=0
ABG 76.8a 140b 235c 500d 500
(49-315) (65-450) (99-1800) (70-2700) (419-750)
n= 124 n= 10 n=7 n=30 n=74 n=3
SH, Simple hyperplasia; LH, linear hyperplasia; MH, micronodular hyperplasia; AH, adnomatoid
hyperplasia
ap < .05 vs. simple.
bp < .005 vs. micronodular.
Cp < .001 vs. micronodular.
dp < .0001 vs. simple
the sporadic ZES subgroup (Fig. 1). On the contrary, in the ABG group, all ECL cell
hyperplasia pattern were present. However, the majority ofpatients showed the presence
ofthe micronodular pattern (59.7 percent). In addition, even ifthe adenomatoid grade was
observed in three patients, it represented only the 2.4 percent oftotal observations.
Table 2 shows the median (range) fasting gastrin levels of the hypergastrinemic
patients subdivided according to the qualitative pattern ofendocrine (ECL) cell. InAGCH
patients no apparent relationship exists between the slight fasting hypergastrinemia and
the qualitative pattern ofendocrine cell. On the contrary, in both ZES and ABG patients,
arelationship between fasting gastrin values and grade ofECLcell hyperplasia seemed to
occur. In fact, ZES patients (including the five MEN I patients) with simple pattern had a
median fasting gastrinemia, which was half of that of patients with the linear one (440
pg/ml vs. 1050 pg/ml), and adenomatoid changes were observed only in the single patient
with the highest levels of gastrin. In the ABG group, no significant difference in median
gastrin levels was achieved between the normal and SH groups. However, the increasing
severity of the pattern of endocrine cell hyperplasia, from simple to micronodular was
associated with a stepwise statistical increase of median fasting gastrin values (Table 2).
In order to verify ifthe fasting gastrin levels were related to the qualitative pattern of
ECL hyperplasia, a correlation analysis between hormonal levels and grade ofhyperplasia
for all the four patient's group investigated (n = 169), was performed (see material and
methods). Spearman rank test was highly significative (r = 0.5580, p < 0.0001), indicating
that the greater were the gastrin levels, the higher was the degree of severity of ECL
hyperplasia pattern.
To evaluate thepattern ofgastrin response tophysiologic stimulus, aprotein-rich meal
was performed in a sample ofpatients from each group. Figure 2 shows, as expected, that
tumoral gastrin levels were substantially not affected by the meal. On the contrary, inABG
the meal test was able to significantly increase, for all the time ofobservation, the already
elevated basal gastrin levels (p < .05). In addition, a more prolonged stimulatory effect of
the meal was observed during all the two-hour test inABG patients, compared to the levels
observed in AGCH and controls, indicating a pronounced and protracted gastrin response
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Figure 2. Median values for gastrin plasma concentration before, during and after proteic
meal in controls (n = 10) (F); AGCH patients (n = 10) (.); ZES patients (n = 10) (+); and
Atrophic body gastritis (n = 25) (*). Full line indicates the length of the meal.* Mann Whitney
rank test two-sided p <0.05 ofABG compared with AGCH and controls.
inthe atrophic patients. AGCHpatients hadasignificantly highergastrin increase inresponse
to meal than controls (p < .01), with a tendency to remain elevated at the end of test.
The different percentage in qualitative pattern observed in body endocrine cells in the
hypergastrinemic conditions were analyzed by morphometric analysis in a representative
number for each condition reflecting the relative percentage pattern of hyperplasia (see
Figure 1). Figure 3 shows the total volume density (TVD) ofCgA-positive endocrine cell
ofthe gastric body mucosa observed at diagnosis. Control andAGCH patients had a over-
lapping median TVD. AGCH patients had a statistical lesser number ofECL cells than all
other hypergastrinemic patients evaluated. ZES patients had a five-fold TVD than that of
control group (2.77 percent [1.53-5.8] vs. 0.73 percent [0.24-1.50]; p < .005), being not
different if analyzed separately for the presence of MEN I. Median total volume density
ofECL cells ofABG patients was about seven-fold the control values and more than two
times that ofZES (6.04 percent [3.4-7.58] vs. 2.77 percent [1.53-5.8]; p < .05).
DISCUSSION
In this study, we have investigated the role of hypergastrinemia in the determination
ofECL cell qualitative pattern ofproliferation in the human gastric body mucosa. To this
purpose, a series ofconsecutive patients withABG, ZES andAGCH were selected on the
basis of screening programs and studied at the time ofdiagnosis.
In respect to the other group of patients, the initial picture of patients with ABG
showed a more severe qualitative histopathological pattern of endocrine cell, since the
micronodular pattern was present in the 59.7 percent oftotal atrophic patients. In contrast,
most ZES and all theAGCH patients, at the momentofdiagnosis, showed less severepatterns
ofendocrine cell hyperplasia. InZES, the normal pattern, however, was neverobserved, the
SH and LH pattern predominated, while the micronodular was infrequent as previously
observed [11, 20]. These distinct patterns found at diagnosis are due to different gastrin
levels as shownby the highly significant correlation between hormonal values andqualitative
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Figure 3. Median and range values for total volume density ofECL express as percentage in
the controls (n = 6), AGCH (n = 6), ZES patients (n = 10), ZES MEN I (n = 5) and ABG
patients (n = 14). Full line indicates median values.* vs. ZES p< 0.05; vs. ZES MEN I p< 0.01; vs.
AGCH p< 0.01; vs. control p< 0.01. ** vs. AGCH p < 0.05; vs. controls p< 0.05. *** vs. AGCH p
< 0.05; vs. controls p< 0.05.
grade ofhyperplasia. Moreover, in these diseases, different time of exposure to the trophic
stimulus of gastrin before the diagnosis should also be considered. In fact, ABG is a barely
symptomless disease whose course prior to diagnosis may be estimated in terms of
decades of life [30-31], resulting in a long-term exposure to elevated gastrin levels. In
contrast, given theclinically more active andmanifest nature ofZES, development ofsymp-
toms to the time ofdiagnosis is relatively short, three to six years [14]. In theAGCH group,
characterized by a severe duodenal ulcer disease, the time before diagnosis is similar to
that ofZES patients, but the mildly elevated levels offasting gastrin well reflect the milder
qualitative pattern observed (i.e., normal and simple hyperplasia).
Another aspectthat mustbe evaluated analyzing the differences in the qualitative pattern
of ECL in our hypergastrinemic patients is the origin of hypergastrinemia, which is dif-
ferent for each human diseases considered. ZES is atumoral disease where gastrin secretion
proceeds unrelated to the acid feed-back or to physiologic stimuli as meals, determining
a continuous exposure of ECL cells to severely and constantly elevated gastrin levels,
where the role ofstimulated gastrin levels is minimal ifnot irrelevant. Atrophic body gas-
tritis is characterized by a secondary G cell hyperplasia due to the lack of physiological
negative feed-back between acid and antral gastrin secretion. Thus, ABG fasting gastrin
levels well reflects the extent ofthe oxyntic damage and express the wide range ofmucosal
alteration present in this disease [13]. Moreover, due to occurrence ofG cells hyperplasia,
these patients had a more prolonged and sustained gastrin response to the meal, which
adds, for several hours ofthe day, a supplemental amount ofgastrin to the already elevated
hormonal values, thus suggesting thatduring the dayABGpatients' ECLcells are exposed
to a dual gastrin modulation: the fasting hypergastrinemic background and the additional
amount induced by meals.
AGCH syndrome arises from an unbalanced regulation between antral G and D cell,
related to the H. pylori infection [17]. These patients display slightly elevated fasting gas-
trin levels and a moderate meal-induced hypergastrinemia, well different from the gastrin
values observed in ABG and ZES patients. Thus, although the behavior of daily gastrin
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secretion is similar to that of atrophic patient, the magnitude of gastrin release is signifi-
cantly lesser, as also reflected by the predominance of milder pattern of hyperplasia in
AGCH patients.
However, if one compares the median fasting gastrin values in the different groups,
it can be noted that at the same pattern ofhyperplasia, overlapping median levels ofgas-
trinemia do not correspond. For example, the simple pattern is found with quite different
median gastrin values: ZES, 440 pg/ml; AGCH, 59 pg/ml; andABG, 140pg/ml. This finding
suggests that gastric mucosa status (atrophic or hypertrophic changes) is another possible
key factor influencing the supposed evolutive sequence ofECL cell pattern. In particular,
it has been suggested that the MH pattern is not exclusively due to the gastrin trophic
effect exerted on the ECLcells but may also represent an epiphenomenon ofmucosal atrophy
due to the persistence of endocrine cells after disappearance of the other epithelial com-
ponents [32-33]. On the other hand, in the non-atrophic gastric mucosa of ZES patients,
the high gastrin levels were only associated with minimal prevalence of micronodules,
thus the role ofmucosal height deserves a careful investigation in order to exclude apparent
differences only due to epithelial alteration.
It has been observed as in ZES the most advanced hyperplasia pattern (micronodular
and adenomatoid) occur almost exclusively in patients with MEN I [21]. Unexpectedly,
we observed that this did not occur in our population, in fact one sporadic ZES patient
showed the presence of MH, while another one had the adenomatoid. We have no data
able to explain this occurrence, but we think that one possible explanation can be found in
the effect ofprolonged pharmacological treatment. In fact, the marked inhibition ofgastric
acid secretion produced by the use ofantisecretory drugs has been suggested as a possible
cause for the increase in gastrin level and for the consequent increase ofECL cell in ZES
patients [20].
The different percentage in prevalence of qualitative ECL cells pattern observed in
the hypergastrinemic conditions, were further supported by morphometric analysis. The
total volume density ofECL cells in controls and AGCH patients overlapped, in keeping
with the observed presence ofthe normal, or atmaximum, ofthe SH pattern. TVD ofspo-
radic ZES was not different from that ofZES MEN I patients, supporting the lack ofdif-
ferences in qualitative findings and in fasting gastrin levels between these two subgroups
found in this study. Interestingly, ABG patients showed the most elevated TVD values,
more than two times those of ZES, suggesting again that more than the absolute gastrin
levels, the time (decades) ofexposure to trophic hormone could be crucial.
In conclusion, our data further support the concept ofgastrin as the selective contrib-
utor to the development and progression ofECLcell hyperplasia in humans. However, the
mucosal status of the hypergastrinemic patients remains to be clarified in detailed and
comparative studies.
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